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ttp://dx.doi.org/10.1016/j.jmoldx.2013.09.003Next-generation sequencing (NGS) is becoming a common approach for clinical testing of oncology
specimens for mutations in cancer genes. Unlike inherited variants, cancer mutations may occur at low
frequencies because of contamination from normal cells or tumor heterogeneity and can therefore be
challenging to detect using common NGS analysis tools, which are often designed for constitutional
genomic studies. We generated high-coverage (>1000) NGS data from synthetic DNA mixtures with
variant allele fractions (VAFs) of 25% to 2.5% to assess the performance of four variant callers, SAMtools,
Genome Analysis Toolkit, VarScan2, and SPLINTER, in detecting low-frequency variants. SAMtools had the
lowest sensitivity and detected only 49%of variants with VAFs of approximately 25%; whereas the Genome
Analysis Toolkit, VarScan2, and SPLINTER detected at least 94% of variants with VAFs of approximately
10%. VarScan2 and SPLINTER achieved sensitivities of 97% and 89%, respectively, for variants with
observed VAFs of 1% to 8%, with>98% sensitivity and>99% positive predictive value in coding regions.
Coverage analysis demonstrated that >500 coverage was required for optimal performance. The spec-
iﬁcity of SPLINTER improved with higher coverage, whereas VarScan2 yielded more false positive results at
high coverage levels, although this effect was abrogated by removing low-quality reads before variant
identiﬁcation. Finally, we demonstrate the utility of high-sensitivity variant callers with data from 15
clinical lung cancers. (J Mol Diagn 2014, 16: 75e88; http://dx.doi.org/10.1016/j.jmoldx.2013.09.003)Supported by the Departments of Pathology and Genetics, Washington
University, St. Louis, Missouri. The Genome Technology Access Center at the
Department ofGenetics,WashingtonUniversitySchool ofMedicine, is partially
supported by NCI Cancer Center Support grant P30 CA91842 to the Siteman
Cancer Center and by ICTS/CTSA grant UL1RR024992 from the National
Center forResearchResources, a component of theNational InstitutesofHealth,
and the National Institutes of Health Roadmap for Medical Research.Molecular testing is gaining an increasing role in the diag-
nosis and management of cancer. In recent years, numerous
studies have shown that speciﬁc somatic mutations and the
mutational status of certain genes can either inform prognosis
(eg, BRCA1/2 in breast/ovarian cancer; IDH1 in glioblas-
toma; and KIT, DNMT3A, IDH1/2, FLT3 ITD, and NPM1 in
acute myeloid leukemia) or predict response to targeted
therapies (KRAS/EGFR antibody therapy and KIT/tyrosine
kinase inhibitors).1e8 The expanding catalog of clinically
relevant mutations has led to the development of high-
throughput assays for detecting somatic mutations directly
from cancer specimens by combining targeted capture with
next-generation sequencing (NGS) platforms. These ap-
proaches can provide comprehensive mutational proﬁling
across a large number of genes simultaneously, with greatlystigative Pathology
.increased efﬁciency and decreased cost as compared with
conventional sequencing methods.9 To date, this approach
has been successfully implemented in several clinical labo-
ratories for detection of somatic mutations in cancer.10,11
Despite their promise, sequencing-based assays for detecting
somatic mutations in cancer pose unique technical challenges
compared with those used to detect constitutional variants.
Cancer specimens from small biopsy specimens may contain
Spencer et alfew tumor cells, and both small and large specimens may
contain substantial amounts of normal tissue, stromal compo-
nents, and inﬂammatory cells. This can result in dilution of
tumor DNA with that from nontumor cells, and thus even so-
matic mutations present in every tumor cell are present at low
frequencies in the sample DNA. In addition, recent studies of
both solid and hematologic cancers have demonstrated
remarkable genetic heterogeneity; although tumors are typi-
cally derived from a single founding clone deﬁned by somatic
variants present in every tumor cell, there are often multiple
tumor cell subpopulations with additional somatic var-
iants.12e16 Also, somatically acquired aneuploidies and copy
number variation are common in many solid tumor types, and
gains or loss of genetic material can alter the observed allele
fraction of sequence variants in these regions.17 NGS-based
detection methods can capture low-frequency mutations
because they provide a digital readout of sequence variants and
high sequencing redundancy from hundreds to thousands of
individual DNA molecules. However, a priori detection of
low-frequency mutations (ie, detection of variants at non-
hotspot positions in which the previous probability of a
variant is low) relies on methods that are able to differentiate
true variants from noise such as sequencing errors and align-
ment artifacts. In the absence of such algorithms, large numbers
of false positive variants may be called because the inherent
error rate of NGS platforms alone can approach 1%. Currently,
many popular NGS analysis programs are designed for
constitutional genome analysis in which variants are expected
to occur in either 50% (heterozygous) or 100% (homozygous)
of reads.18,19 These previous probabilities are often built into
the detection algorithms, and variants with variant allele fre-
quencies (VAFs) falling too far outside the expected range for
homozygous and heterozygous variants may be considered of
poor quality and not be called because of the high likelihood
that they are false positive rather than inherited variants. Several
groups have developed experimental20,21 and/or bioinfor-
matics22e27 approaches for low-frequency variant detection
that have been shown to detect variants at frequencies of 0.1%
and lower. These methods typically require specialized library
preparation, spiked-in control samples, or other modiﬁcations
to standard NGS laboratory protocols to detect variants with
<2% VAF. Moreover, some have been used only for low-
frequency variant detection using whole genome or PCR
enrichment strategies, and experience with application of these
methods to data from other enrichment methods, such as hy-
bridization capture, are limited.
Streamlined protocols for standard NGS library prepara-
tion and target enrichment using hybridization capture are
now relatively common and have made it attractive for clin-
ical molecular laboratories to adapt these methods for detec-
tion of somatic mutations directly from cancer samples.
However, there are few data on the performance of this
workﬂow for detecting low-frequency variants in deep
coverage sequence data from a single sample (ie, not a
tumorenormal sample pair) using common NGS variant
detection tools, which are widely used and cited but have76typically been developed for detection of inherited variants in
low-coverage NGS data. In the present study, we used a
laboratory-derived dilution series of well-characterized
HapMap DNA samples to determine the performance of
common analysis tools in detecting low-frequency variants in
hybridization capture NGS data. We tested three widely used
programs, SAMtools (version 0.1.18)), Genome Analysis
Toolkit (GATK; UniﬁedGenotyper version 2.3), and Var-
Scan2 (version 2.3.5; compared in Supplemental Table S1),
and one high-sensitivity algorithm that creates instrument-run
and context-dependent error models (SPLINTER; version 6t)
to analyze high-coverage (>1000), hybridization capture
NGS data for 26 cancer genes from mixed HapMap samples
with a range of expected minor variant frequencies of 25% to
2.5%.18,19,25,27 The performance of these tools was assessed
using a set of gold standard single nucleotide variants (SNVs)
obtained by sequencing the pure HapMap samples individu-
ally. We also examined the effect of various coverage depths
on low-frequency allele detection and tested each program
using a set of 15 routine lung adenocarcinoma specimens to
gauge the practical effect of applying these tools to clinical
samples. Our results showed that there is considerable vari-
ability in the sensitivity for low-frequency variants across the
programs tested and that some of the most popular tools
perform poorly at even moderate VAFs. However, we found
that GATKperformedwell for variants withVAFs10%and
that SPLINTER and VarScan2 showed good sensitivity even
at the lowest VAF tested, <5%, with acceptable positive
predictive value (PPV) in clinically interpretable regions.
Materials and Methods
DNA Extraction
HapMapDNAsamples used in the present studywere obtained
from the Coriell Cell Repository (Coriell Institute for Medical
Research, Camden, NJ) as cell lines and included samples
NA17989, NA18484, NA18507, NA18872, and NA19127.
Cells were grown under standard conditions, and DNA was
prepared using the QIAamp DNA Micro Kit (Qiagen, Inc.,
Valencia, CA) per the manufacturer’s instructions. The DNA
concentration for each sample was determined using a Qubit
ﬂuorometer (Life Technologies Corp., Grand Island, NY).
Mixed samples were created bymixingDNA from one sample
(NA17989; Chinese ethnicity) with each of the four others
(NA18484, NA18507, NA18872, and NA19127; all of
Yoruban ethnicity) in the amounts given in Table 1. DNA from
the 15 formalin-ﬁxed, parafﬁn-embedded (FFPE) lung ade-
nocarcinomas was extracted as previously described.28
Library Preparation, Multiplex Sequencing, and Data
Preprocessing
Illumina sequencing libraries were prepared using 1 mg
genomic DNA following standard protocols as recom-
mended by the manufacturer. DNA was ﬁrst sheared tojmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Description and Sequencing Results for Pure and Mixed HapMap Samples
Sample
Input DNA, mg
(% of mix)z
Expected
VAF, %x
Observed
VAF, %{
Sequencing results* Gold standard SNVsy
Reads (millions) Coverage (mean) Total (unique)
Pure Samples
NA17989 1 14.8 1417 231 (NA)
NA18484 1 16.8 1158 294 (113)
NA18507 1 20.4 1796 277 (101)
NA18872 1 17.7 1619 278 (115)
NA19127 1 21.9 1816 254 (98)
Mixed Samples
NA18484_50 0.5 (50) 25 26.0 24.6 1469
NA18507_50 0.5 (50) 25 25.5 21.8 1493
NA18872_50 0.5 (50) 25 26.1 28 1583
NA19127_50 0.5 (50) 25 25.5 26.1 1200
NA18484_20 0.2 (20) 10 11.5 22.2 1594
NA18507_20 0.2 (20) 10 10.5 19.9 1476
NA18872_20 0.2 (20) 10 12.6 21.5 1529
NA19127_20 0.2 (20) 10 9.8 16 1229
NA18484_10 0.1 (10) 5 6.2 23 1822
NA18507_10 0.1 (10) 5 9.2 19.7 1598
NA18872_10 0.1 (10) 5 6.5 21.6 1817
NA19127_10 0.1 (10) 5 5.6 19.5 1667
NA18484_5 0.05 (5) 2.5 4.4 24.6 1969
NA18507_5 0.05 (5) 2.5 4.9 22.7 1929
NA18872_5 0.05 (5) 2.5 4.1 24 1909
NA19127_5 0.05 (5) 2.5 3.3 19.8 1649
*Sequencing results are shown for unique reads that mapped to the assay target regions with a mapping quality score >20.
yGold standard variants were identiﬁed and reviewed as described (see Materials and Methods). Total variants include only those in the targeted regions
called by both the variant identiﬁcation programs GATK and SAMtools and had a coverage of at least 50. Numbers in parentheses indicate unique heterozygous
variants not present in NA17989 (ie, minor gold standard variants).
zMixed samples contained the indicated amount of DNA plus additional DNA from NA17989 to total 1 mg.
xExpected VAF of unique heterozygous alleles relative to NA17989 for each minor sample.
{Observed VAFs calculated from base counts at minor gold standard variant positions.
SNVs, single nucleotide variants; VAFs, variant allele fractions.
Low-Frequency NGS Variant Detectionobtain approximately 300 bp fragments using a Covaris
E210 instrument (Covaris, Inc., Woburn, MA), then end-
repaired, ligated to indexed universal adapters for multiplex
sequencing, and ampliﬁed via limited cycle PCR. Libraries
were enriched using the Washington University comprehen-
sive cancer set WUCaMP27 version 1.0 (Genomics and Pa-
thology Services, Washington University, St. Louis, MO)
(Supplemental Table S2) using Agilent SureSelect capture
probes (Agilent Technologies, Santa Clara, CA). Quality
control procedures for library preparation included veriﬁca-
tion of fragment size using an Agilent 2100 Bioanalyzer and
post-capture real-time quantitative PCR quantiﬁcation. All 21
enriched libraries (ﬁve pure HapMap samples and 16 mixed
samples from four dilutions for each of four HapMap sam-
ples) were then pooled and sequenced on an Illumina HiSeq
2000 instrument (Illumina, Inc., San Diego, CA) using V3
chemistry to obtain paired-end 101-bp reads using standard
sequencing parameters and on-instrument quality control
procedures; pure libraries were sequenced together in one
lane, and mixed libraries were pooled in equimolar amounts
and sequenced in a separate lane. The resulting sequence data
were demultiplexed and mapped to the hg19 human referenceThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsequence using Novoalign version 2.08.02 (Novocraft Tech-
nologies, Sdn Bhd, Selangor, Malaysia). Mapped data were
preprocessed to mark duplicate reads before all downstream
variant identiﬁcation analyses. Command line parameters for
all processing steps are given in Supplemental Table S3.
Gold Standard Variant Identiﬁcation
Sequence data from the ﬁve pure HapMap samples were
analyzed using GATK (UniﬁedGenotyper version 2.3) and
SAMtools (version 0.1.18) using the Best Practices guide-
lines for read realignment and quality score recalibration of
the data before variant identiﬁcation with default parameters
for each program (Supplemental Table S3) to obtain gold
standard heterozygous and homozygous variant calls
including SNVs and insertion/deletion variants (indels).
Only variants called by both programs at positions with a
coverage depth of at least 50 were included in this set, and
variants called by only one program were discarded. All
discordant, false positive, and low coverage (<50) positions in
the gold standard datasets were masked from subsequent an-
alyses. Because there was no agreement in the exact indel calls77
Spencer et albetween SAMtools and GATK, all were excluded from this
analysis; indel positions 5 adjacent bp were also masked
from all downstream analyses because most of these calls
occurred in noncoding regions with low sequence complexity
in which true polymorphisms may exist but which are chal-
lenging to resolve deﬁnitively, in particular across multiple
variant callers. Heterozygous gold standard SNVs unique to
the minor HapMap sample (termed minor gold standard var-
iants) in each mixed sample were identiﬁed using custom
scripts that executed the intersectBed utility of the BEDTools
package.29 Inasmuch as no gold standard indels were id-
entiﬁed using this approach, we identiﬁed all indels called by
either GATK or SAMtools and selected 45 for validation via
Sanger sequencing across all HapMap samples. Primers were
designed ﬂanking the putative indels for PCR ampliﬁcation,
followed by exonuclease and phosphatase treatment, Sanger
sequencing, and capillary electrophoresis. Of these, ﬁve
distinct indel variants were validated that were heterozygous
and not present in the NA17989 HapMap sample and thus
were used in the indel analysis of the mixed samples.
Mixed-Sample Analysis
All data from mixed HapMap samples were analyzed using
GATK (version 2.3), SAMtools (version 0.1.18), VarScan2
(version 2.3.5), and SPLINTER (version 6t), using custom
scripts to execute each program. All programs were executed
with default parameters exceptwhere indicated (Supplemental
Table S3), although additional parameter conﬁgurations were
also explored in an attempt to increase the sensitivity for low-
frequency variants. Speciﬁcally, GATK and SAMtools pa-
rameters for internal down-sampling of reads to a prespeciﬁed
depth (usually approximately 250), which could eliminate or
reduce the frequency of minor variants simply through sam-
pling, were set to a higher value (eg, we used values of at least
8000). We also discovered one parameter in the GATK pro-
gram (version 2.0 or later) that intentionally down-weights
variants that are at low frequency (the contamination
parameter), which must be turned off to detect any low-
frequency variants. For indel detection, we also changed the
-minIndelCnt and -minIndelFrac parameters to 1 and 0.01,
respectively. For all tools, only variants that passed default
internal ﬁlters were considered (eg, variants with the str10
strand bias ﬁlter in VarScan2 were excluded); however, no
additionalﬁlterswere applied.Analysis usingSPLINTERwas
performed as described previously.27 In brief, reads were
mapped using Novoalign and processed using SPLINTER
with a cycle cutoff of 60 and a run-speciﬁc error model
generated from the M13 phage vector sequenced in the same
lane as a separately indexed sample. SPLINTER cutoff values
for variant identiﬁcation are given in Supplemental Table S3.
SPLINTERoutputwas converted to variant cell format using a
custom Perl script (available on request). In addition, in the
event that SPLINTER reported multiple alleles at a single site,
only the variant with the greatest VAF was considered. Pa-
rameters for all programs are given in Supplemental Table S3.78Performance analysis used the BEDTools intersectBed
and custom awk commands (available on request) to iden-
tify the minor gold standard variants present among the
variant calls for each mixed sample. Speciﬁcity analyses
were performed subsequent to masking of discordant, indel,
and low coverage positions identiﬁed during generation of
the gold standard variant sets and excluded all indel calls
made by each program.
Sensitivity was calculated as follows:
Sensitivityð%ÞZ Minor gold standard variants detected
Total minor gold standard variants
 100
ð1Þ
PPV was calculated as follows:
PPVð%ÞZ Total gold standard variants detected
Total variants called
 100 ð2Þ
where the total gold standard variants included gold standard
variants in both NA17989 and the minor sample in mixed
samples, and the total variants called included all SNVs called
after exclusion of any positions thatweremasked because of low
coverage (<50), discordant calls, or indels 5 bp in pure gold
standard samples (see Gold Standard Variant Identiﬁcation).
Conﬁdence intervals were calculated using the binomial distri-
bution in R (version 2.15.1; R Project for Statistical Computing,
http://www.r-project.org, accessed June 1, 2012).
Coverage analysis was performed using the Picard
DownsampleSam function to randomly sample reads from
the mixed dataset BAM ﬁles using sampling probabilities
calculated as follows:
PðsamplingÞZ Desired coverage
Total coverage
ð3Þ
where desired coverage was 1500, 1250, 1000, 750, 500,
400, 200, or 100 and total coverage was the mean per-base
coverage across the target region for each sample. In some
mixed samples the highest coverage set was 1250 because
the mean coverage in the original dataset was <1500. All
down-sampled ﬁles (n Z 121) were then analyzed as
described to identify minor gold standard variants, and a
custom Perl script was used to calculate the mean sensitivity
for each mix (50%, 20%, 10%, or 5%) at positions with
minimum observed coverages in bins of 100 (0 to 99, 100 to
199, and so on) across all mixed samples.
Read Quality Filtering
Quality ﬁltering of reads was performed using a custom Perl
script that accepted output from the SAMtools view com-
mand, which includes mapping quality, individual base
qualities, and discrepancies with the reference sequence for
each read. The script parsed this information and printed
only lines corresponding to reads with a user-deﬁned min-
imum mapping quality (set to 20), minimum base quality for
all bases in the read (set to 20), and maximum number of
discrepancies (set to 4).jmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 1 A: Theoretical probability of sam-
pling variant alleles of differing frequencies (25%,
10%, 5%, and 2.5%) two or more times versus
coverage depth, based on binominal sampling
statistics. B: Distribution of observed minor gold
standard VAFs for all mixed samples. Each curve
represents the distribution for a single sample
with mixture proportions of 50%, 20%, 10%, and
5%, which were expected to have VAFs of 25%,
10%, 5%, and 2.5%, respectively. Gray bars show
the middle 95% for each expected distribution.
Low-Frequency NGS Variant DetectionAnalysis of Lung Adenocarcinoma Samples
NGS data from formalin-ﬁxed lung adenocarcinoma sam-
ples were previously generated using the same platform
(WuCaMP27) as part of a separate study comparing formalin-
ﬁxed and fresh-frozen specimens for NGS analysis; tu-
mor cellularity for these cases is shown in Supplemental
Figure S1.28 These data were reanalyzed with the four
variant identiﬁcation programs using the same methods as
described except only coding regions were analyzed and
variants at VAF <2% were excluded. An additional analysis
step included functional annotation of detected variants using
theANNOVAR software package (version 2012Oct23) using
default parameters.30 A limited mixing study was also per-
formed on two lung adenocarcinoma samples using 500 ng of
two samples to generate a 50:50 mix sample (25% minor
sample VAF) and 800 ng of one sample and 200 ng of another
sample to generate an 80:20 mixed sample (10% minor
sample VAF). Sequencing was performed as described for
eachmixed sample and for the two pure samples individually.
Analysis was performed as described for the HapMap gold
standard samples and mixes.Results
We used DNA extracted from HapMap cell lines to generate a
dilution series of samples with deﬁned mixture proportions to
study the performance of common NGS analysis tools for
detecting low-frequency variants. DNA from each of four
HapMap samples (NA18484, NA18507, NA18872, and
NA19127) was mixed with a ﬁfth, ethnically distinct sample
(NA17989) at proportions of 50%, 25%, 10%, and 5% by
mass for a total of 16 mixed samples (Table 1). DNA, 1 mg,
which is equivalent to approximately 3 105 haploid genome
copies, for each mixed sample and the ﬁve individual samples
was used as input for library construction and subsequent
enrichment for coding and noncoding sequences for 26
cancer genes (Supplemental Table S2) and multiplex Illu-
mina sequencing. The pooled sequencing experiments were
designed to produce at least 1000 mean coverage of the
targeted regions for each sample so that detection of low-The Journal of Molecular Diagnostics - jmd.amjpathol.orgfrequency variants would not be limited by sampling. This
high coverage requirement was predicted by simulations
using binomial statistics, which showed that coverage depths
as high as 200 predict only approximately 90% probability
of observing two reads with a heterozygous variant present
in the minor population at a mix proportion of 5% (expected
VAF of 2.5%), the lowest in the present study (Figure 1A).
Sequencing Results and Gold Standard Variant
Identiﬁcation
Sequencing resulted in a mean of 21 million reads (range, 14
million to 28 million) for each mixed and pure sample in the
study (Table 1). Read quality and mapping statistics were
examined and found to be similar for all sequenced samples.
Coverage analysis revealed a mean coverage across the entire
target region of 1606-fold for all samples (range, 1155 to 1969)
and that a mean of 91% (range, 89% to 92%) and 81% (range,
75% to84%)of the targeted positions in each sample had 500
and 1000 coverage, respectively. Complete sequencing and
read mapping statistics are given in Supplemental Tables S4
and S5 for pure and mixed samples, respectively.
Two standard variant identiﬁcation programs, GATK and
SAMtools, were then used to identify all SNVs in the ﬁve
pure samples to establish a set of gold standard SNVs for all
subsequent analyses. These programs were used because
their performance in identifying constitutional variants has
been established in a large number of genomic studies.18,31,32
Variant identiﬁcation was performed jointly on all samples,
and discordant calls were masked in downstream analyses
(see Materials and Methods). This resulted in 602 distinct
gold standard SNVs across the ﬁve HapMap samples, with a
mean of 267 per sample (range, 231 to 294). Of all identiﬁed
SNVs, 97.7% (588 of 602) were present in dbSNP (version
137), and 100% of the genotypes that overlapped publically
available, array-based HapMap genotypes for these samples
were concordant; those variants that were not present in
dbSNP were also included in the gold standard set, all of
which seemed to be high-quality inherited variants onmanual
review. Variants were subsequently extracted for each sam-
ple used in the dilution series that were unique relative to
NA17989 (which was used as the major sample in the79
Spencer et aldilution series) and heterozygous because these were ex-
pected to occur at VAFs that were half that of the mix pro-
portion in the mixed samples (ie, 25%, 10%, 5%, and 2.5%).
There were 427 of these minor gold standard variants across
the four mixed samples (mean per sample, 107; range, 98 to
115), including 56 coding region variants (mean per sample,
14; range, 8 to 21), which were used to evaluate the perfor-
mance of variant identiﬁcation programs for detecting low-
frequency variants.
In addition to these gold standard SNVs, we also identi-
ﬁed a small number of insertions and deletions in the
HapMap samples to assess the performance of the software
tools for detection of indel variants. Because no concordant
indels were identiﬁed via both GATK and SAMtools in the
gold standard analysis, we reviewed potential indel calls
made by either program and selected a subset that were not
in microsatellites or long homopolymer runs for validation
via Sanger sequencing. This resulted in ﬁve distinct Sanger-
validated indel calls (three deletions and two insertions) of 1
to 6 bp (Supplemental Figures S2, S3, S4, S5, and S6) that
were suitable for analysis in the mixed samples; none oc-
curred in coding regions, and several were in regions
adjacent to low-complexity sequences.
Observed VAFs
Before testing the low-frequency variant detection perfor-
mance, we examined the observed frequencies of the minor
gold standard variants to determine whether any allele bias
occurred during targeted sequencing and to verify the VAFs
in the mixes. This demonstrated that heterozygous minor
gold standard variant VAFs generally fell within the expected
range, although SNVs in the 10% mix had a mean VAF of
6.8% rather than the expected 5%, and the mean VAF of the
5% mix was 4.2% rather than 2.5% (Table 1 and Figure 1B).
Inasmuch as mixing to make the most dilute samples
involved DNA volumes as low as 1 mL, this discrepancy was
likely due to inaccurate DNA quantitation and/or pipetting
errors. However, despite these differences, the overall
concordance between observed and expected VAFs in the
mixed samples demonstrated that targeted hybridization
capture did not bias enrichment against non-reference alleles
in the sample, even though the capture reagents were
designed from the human reference sequence and did not
account for non-reference alleles present in the HapMap
samples. In addition, this analysis veriﬁed that the lower
boundary of VAFs in our dilution series was <5%.
Low-Frequency SNV Identiﬁcation
We used four publicly available NGS software tools to
identify SNVs in the mixed samples. The programs we
tested included the variant identiﬁcation functions of pop-
ular tools SAMtools and GATK, which use bayesian
genotype-calling algorithms, the somatic mutation program
VarScan2, which uses a set of heuristic read and base80quality ﬁlters, and SPLINTER, a low-frequency variant
caller originally designed to detect rare alleles in pooled
samples using custom run-speciﬁc error models based on
large deviation theory.18,19,25,27 These programs were
executed as described (seeMaterials and Methods) to obtain
passing SNV calls (nonpassing variants using default ﬁlters
were excluded) with a coverage depth of at least 100
across the entire target region; a mean of 97.6% of targeted
positions met this coverage gold across all mixed samples
(range, 97.3% to 98.2%). In most cases we used the default
parameters for each program, which provided the best low-
frequency variant performance with an acceptable speci-
ﬁcity (although the best performance was variable, as we
describe in Effect of Coverage on SNV Sensitivity and
Speciﬁcity). However, we found changing some parame-
ters to be critical and used optimized parameters for some
programs (see Materials and Methods). Variant calling
using these methods resulted in identiﬁcation of between
212 and 442 total SNVs across all samples, depending on
the particular mix proportion and program (Supplemental
Table S5). We examined the sensitivity for each program
across a range of variant frequencies by determining the
proportions of minor gold standard variants that were suc-
cessfully detected in the mixed samples; to prevent false
negative results because of incomplete sampling, this anal-
ysis considered only positions in which observed coverage
was 100. Comparison of these sensitivities revealed
substantial differences in performance across the programs
tested. For example, SAMtools detected only 49% [201 of
411; 95% conﬁdence interval (CI), 44% to 54%) of the
minor gold standard variants in the 50% mixes (25.8% mean
observed VAF), and few variants were detected at higher
dilutions (Figure 2A). The other programs performed sub-
stantially better. GATK detected 97% (396 of 409; 95% CI,
94% to 98%) of the minor gold standard variants at the 20%
dilution (11.2% mean observed VAF), although there was a
substantial drop off at lower VAFs (Figure 2A). Indeed, this
program detected 100% of variants with observed VAFs
>10% and detected no variants with observed VAFs <7%
regardless of coverage depth. VarScan2 and SPLINTER
showed the best performance and detected at least 89% of
the minor gold standard variants in each group of mixed
samples. Sensitivity was dependent on VAF, as expected;
however, these programs were still able to detect, respec-
tively, 97% (VarScan2: 396 of 409; 95% CI, 95% to 98%)
and 89% (SPLINTER: 363 of 409; 95% CI, 84% to 91%) of
minor gold standard variants in the 5% mixed samples
(4.2% mean observed VAF). Similar results were observed
using only positions conﬁrmed using array-based HapMap
genotypes for all mixed samples (Supplemental Figure S7),
and no differences in the minor gold standard variant calls
were identiﬁed in one dilution series after remapping of the
reads with a different program, BWA (data not shown). In
most cases, minor gold standard variants that were not
detected by these programs had lower coverage than those
that were detected. For example, 17 of the 19 variantsjmd.amjpathol.org - The Journal of Molecular Diagnostics
Low-Frequency NGS Variant Detectionmissed by VarScan2 occurred at positions with <200
coverage. Variants missed by SPLINTER had more variable
coverage but frequently occurred at low coverage positions
or had VAFs such that the variant allele was present in <25
reads in the sample.
We also assessed the performance of each program for
detecting the minor gold standard variants present in coding
regions and splice sites of the 26 targeted genes, which
included 20% of the total targeted sequence of 61,221 bp
(Supplemental Figure S8). There were a total of 56 coding
variants among the four mixed samples in each dilution set,
with a mean per sample of 14 (range, 8 to 21). Similar to the
results for the entire target region, SAMtools demonstrated
the poorest performance, detecting only 64% of the coding
region variants in the 50% mix sample (36 of 56; 95% CI,
50% to 77%). GATK detected all of the coding region vari-
ants in the 50% mix and all but one variant in the 20% mixed
sample (sensitivity 98%; 95% CI, 90.4% to 99.9%), but few
variants in the more dilute samples. VarScan2 missed only
one coding variant with a VAF of 5.4% that occurred at a
position with relatively low coverage (111) in a 5% mixed
sample (sensitivity 98%; 95% CI, 90.4% to 99.9%), whereas
SPLINTER achieved sensitivity between 96% and 98%
across the four dilution sets, with the missed variants occur-
ring at positions with coverage <600.
Sensitivity was also evaluated for the gold standard var-
iants present in the major HapMap sample in the dilution
series to compare the performance of the programs for
variants present at higher frequencies. The major gold0
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The Journal of Molecular Diagnostics - jmd.amjpathol.orgstandard variants in this analysis had expected VAFs of at
least 25%, reﬂecting either heterozygous or homozygous
variants diluted by a maximum of 50% with the minor
HapMap sample. These sensitivities showed minor differ-
ences between the programs, with GATK and VarScan2
exhibiting the best performance. However, with the excep-
tion of SAMtools in the 50% mixed sample, all programs
detected at least 91% of the variants, and performance was
similar across all dilutions (Figure 2B).
Speciﬁcity and PPV
To determine whether there was a tradeoff between sensi-
tivity and speciﬁcity across the variant identiﬁcation pro-
grams, we identiﬁed variants in each mixed sample that were
not present among the gold standard variants in either Hap-
Map sample in the mix and were therefore likely to be false
positive calls. Although some of these variants could be true
positive variants that were missed in our gold standard
analysis, we attempted to minimize this by excluding all
positions that were low coverage or ambiguous in the gold
standard analysis; we believe this approach provides a
reasonable estimate of the speciﬁcity and PPV in interpret-
able regions of our target. This analysis revealed that GATK
and SPLINTER made few false positive calls in any sample
(GATK: mean, 6.6; range, 6 to 8; SPLINTER: mean, 4.6;
range, 1 to 13) and that SAMtools made no false positive
calls (Figure 2C). VarScan2 was the clear outlier, with a
mean of 18.5 false positive calls per sample (range, 13 to 25).100
92
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100
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Figure 2 Performance of GATK, SAMtools, Var-
Scan2, and SPLINTER for detecting low-frequency
variants in mixed samples at positions with
coverage 100. A: Sensitivity for detecting all
heterozygous minor gold standard variants in
samples with mix proportions of 50%, 20%, 10%,
and 5% (mean observed gold standard VAFs, 25.5%,
11.2%, 6.8%, and 4.2%, respectively). Sensitivities
(True positive/True positive þ False negative) are
point estimates based on detection of all minor gold
standard variants at positions with 100
coverage in each set of mixed samples (n Z 409,
406, 409, and 411, respectively). Error bars show
the 95% binomial CI for each point estimate. B:
Sensitivity for detecting homozygous and hetero-
zygous gold standard variants in the major sample,
which have estimated VAFs of >25%. Error bars
show the 95% binomial CI for each point estimate.
C: Mean number of false positive SNV calls per
sample made by each program at the indicated mix
proportion across the entire target region, encom-
passing coding and noncoding sequence of 26
genes (306,336 bp). Indel calls were excluded, as
were positions with low coverage or discordant calls
in the gold standard variant analysis (see Materials
and Methods). Error bars show the SD across all
samples with the indicated mix proportion (nZ 4
for eachmix proportion).D: PPV (True positive/True
positive þ False positive) for SNV calls by each
program across themix proportions. Error bars show
the 95% binomial CI for each point estimate.
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Spencer et alWe calculated the PPV, ie, the proportion of called variants
that were real, for each program by dividing the total number
of gold standard variants identiﬁed (including both major and
minor samples in each mixture) by the total number of var-
iants called. This statistic ranged from 94% to 100% across
the entire dataset, with VarScan2 having the lowest mean
PPV, 95% (Figure 2D).
The vast majority of false positive SNV calls from all four
programs occurred in noncoding regions with low com-
plexity. Indeed, only one false positive call was made in a
coding region by any program, which was a variant with
VAF of 1% in a single sample that was called by VarScan2
(Supplemental Figure S9). There were no false positive calls
in coding regions produced by the other three programs.
Indel Detection Sensitivity
We used ﬁve Sanger-validated indels identiﬁed in two of the
HapMap samples to conduct a limited study of indel detection
sensitivity of the four programs in the mixed samples. For this
analysis, we considered any indel variant of the correct type
(insertion or deletion) called within a 5-bp window of the vali-
dated indel position as correctly identiﬁed because the precise
indel position in a sequence alignment can be arbitrary. Using
this approach, we found that SAMtools detected none of the
validated indels, even in the 50%mixed sample (Supplemental
Table S6). SPLINTER detected only one of the indels,
although it was detected at all mix proportions. GATK de-
tected none of the indels using default parameters; however,
after some optimization (see Materials and Methods), it
detected all ﬁve indels in the 50% and 20% mixed samples,
three ofﬁve in the 10%mixed sample and one ofﬁve in the 5%
mixed sample. In contrast, VarScan2 detected all ﬁve indels at
all mix proportions. Inasmuch as the sample size in this anal-
ysis was small, the results are likely inﬂuenced by factors such
as indel length and sequence context of the speciﬁc variants in
the set. Nonetheless, these results provide some preliminary
indications of indel detection of these programs and suggest
that VarScan2 may be an acceptable option for detecting low-
frequency indel variants. However, we observed that
VarScan2 called a large number of indels in noncoding regions
(mean of approximately 54 per case), many of which were
likely to be false positive on manual review. Although these
spurious calls did not occur in coding regions, and, thus,would
be unlikely to affect clinical interpretations, this observation
suggests that using VarScan2 for indel detection would sub-
stantially increase the total number of variant calls.
Effect of Coverage on SNV Sensitivity and Speciﬁcity
Because coverage depth is likely a critical variable in
detecting low-frequency variants using these programs, we
used a down-sampling approach to determine the minimum
coverage required to conﬁdently identify the minor gold
standard variants in the mixed samples. Sequencing reads
from the mixed samples were randomly sampled to achieve82expected mean coverage depths for the entire target region,
ranging from 100 to 1500, and then the four programs
were used to identify variants in these down-sampled read
sets. The observed coverage depth at each minor gold
standard variant position was also recorded, which allowed
for analysis of variant detection with respect to the actual
coverage at each variant position.
The results of this analysis are summarized in Figure 3,
which shows the sensitivity for minor gold standard variants
as a function of the minimum observed coverage at variant
positions for all four variant detection programs stratiﬁed into
coverage bins of 100. The trends in sensitivity reﬂect what
was observed in the full coverage data: SAMtools demon-
strated poor sensitivity when compared with the other three
programs, and VarScan2 and SPLINTER exhibited the best
performance. As expected, sensitivity was decreased at lower
coverage, with the most precipitous decline occurring at
coverage depths <300. GATK showed a more gradual
decline in sensitivity in the 20% mixed sample (11.2% mean
observed VAF) at coverages<800, but detected>90% of the
minor gold standard variants at coverage depths between 400
and 800; at coverage depths <400, sensitivity decreased
substantially. Compared with the other programs,
SPLINTER also showed a gradual decline in sensitivity with
coverage, with optimal sensitivity occurring at higher cov-
erages (>800). In contrast, the sensitivity of VarScan2
remained at>95% even for the 5%mix (4.2%mean observed
VAF) at coverages of 400 before decreasing at lower
coverage depths.
We also examined the speciﬁcity of each program in the
down-sampled data to determine the effect of varying co-
verage levels on false positive calls (Figure 4). This revealed
that VarScan2 called more false positives as the coverage
increased; there were a mean of 1.4 false positives per
sample in data with coverage of 100 compared with a
mean of 18.5 per sample in the complete dataset (mean
coverage, approximately 1500). This was unexpected
because higher coverage is generally associated with more
conﬁdent base calls. GATK also called more false positives
at higher coverage levels; however, the difference was small
(100 coverage, mean of six false positive calls; 1500
coverage, mean of 8.6 false positive calls). In contrast,
SPLINTER called a large number of false positives at low
coverage levels (eg, >100 for the 100 coverage dataset),
compared with fewer than 20 for the datasets with higher
coverage. Similar to the complete dataset, SAMtools called
virtually no false positives at any coverage level and mix
proportion.
Manual review of selected false positive calls revealed
that some of the variant positions themselves were of high
quality and thus passed variant quality ﬁlters; however, the
reads containing the variants had multiple discrepancies,
which suggested that they were either incorrectly mapped or
of variable quality. This observation provided some expla-
nation for the greater number of false positives called by
VarScan2 in datasets with higher coverage, because thejmd.amjpathol.org - The Journal of Molecular Diagnostics
SFigure 3 Sensitivity of GATK, SAMtools, Var-
Scan2, and SPLINTER for low-frequency variants as
a function of observed coverage at variant posi-
tions. Sequencing reads from mixed samples were
randomly sampled (see Materials and Methods) to
obtain datasets with estimated mean coverage
depths of 1500, 1250, 1000, 750, 500, 400, 200,
and 100 across the entire target region for each of
the mixed samples. The observed coverage depths
were determined for all minor gold standard vari-
ants, and variant detection was performed using
each of the four programs. Panels show the overall
sensitivity for all variants from each mixed sample
in the observed coverage in bins of 100 (eg, the
100 bin contains all gold standard variants with
coverage depths between 0 and 100) for GATK (A),
SAMtools (B), VarScan2 (C), and SPLINTER (D).
Error bars show the 95% binomial CI for each point
estimate.
Low-Frequency NGS Variant Detectiongreater number of reads could result in more instances of
incorrect mapping or low-quality reads that generate false
positive calls. To determine whether additional ﬁltering to
remove multiple-discrepancy and low-quality reads could
reduce the number of false positives and improve speci-
ﬁcity, we created a set of high-quality ﬁltered reads from
each mixed sample, comprised of reads with only high-
quality bases (PHRED quality 20), a minimum mapping
quality score of 20, and fewer than four total discrepancies
per read. This removed 2 million to 9 million reads from the
mixed samples (mean, 5.3 million) and had a relatively
small effect on mean target coverage (mean preﬁltered
coverage, 1620; postﬁltered coverage, 1387). Variant iden-
tiﬁcation in this set of ﬁltered reads using the same set of
parameters as in our initial sensitivity analysis reduced the
sensitivity of GATK and VarScan2 for minor gold standard
variants by 1% to 3% and of SPLINTER by up to 6%
(Figure 5A) because of reduced coverage at some positions.
However, the number of false positive calls made by these
programs was reduced substantially. In the ﬁltered read set
there was a mean of 0.8 (range, 0 to 2) false positive SNVs
per sample for all programs (Figure 5B), compared with 6.7
(range, 6 to 8) false positives for GATK, 18.5 (range, 13 to
25) for VarScan2, and 5.1 (range, 1 to 12) for SPLINTER,
using all reads (Figure 2C). This suggested that a preﬁltering
approach could be used to improve the speciﬁcity, in
particular for VarScan2.The Journal of Molecular Diagnostics - jmd.amjpathol.orgLow-Frequency Variant Detection in Clinical Lung
Adenocarcinoma FFPE Samples
We next used the four programs to identify variants in NGS
data from 15 lung adenocarcinoma specimens to assess low-
frequency variant detection performance in clinical NGS
data. These samples were obtained from diagnostic FFPE
tissue and were sequenced using the same targeted NGS
platform that was used to sequence the HapMap dilution
samples.28 Sequencing results were similar to the HapMap
samples, with mean target coverage of 1100, and 79% of
target positions had coverage of at least 500 (Supplemental
Table S7). Variant identiﬁcation was performed in the same
manner as described above with a few exceptions. Because
no gold standard variants existed for these samples, we
restricted our analysis to variants known to be highly recur-
rent in cancer samples on the basis of their presence in the
COSMIC mutation database.33 Variants were identiﬁed in
coding sequences; then only changes present in COSMIC
were compared between the variant detection programs. In
addition, we required the variants to be present at a frequency
of at least 2% because our dilution series was based on a
minimum VAF of 2.5%.
Approximately 30 total coding region variants were
identiﬁed in the 130 kb of coding sequence in each sample
(range, 22 to 45), about 3 (range, 0 to 7) of which were
nonsynonymous SNVs that were not known polymorphisms83
Figure 4 False positives (mean per sample)
called by GATK, SAMtools, VarScan2, and SPLINTER
as a function of mean target coverage and mix
proportion across the entire target region encom-
passing coding and noncoding sequences of 26
genes (306,336 bp). Variant SNV calls in down-
sampled data that were not among the gold stan-
dard SNVs were called as false positive, after
excluding indel calls and positions that were low
coverage (<50) or discordant in the gold standard
analysis. The number of false positive calls for GATK
(A), SAMtools (B), VarScan2 (C), and SPLINTER (D)
for each down-sampled coverage level and the mix
proportion indicated by the legend. Error bars show
the SD for each coverage level and mix proportion.
Spencer et alpresent in dbSNP (version 137), and all four programs called
a similar number of coding region and nonsynonymous
variants in each case (Supplemental Table S8). In three cases,
no variants were identiﬁed that were present in the COSMIC
database, whereas in the remaining 12 cases, 15 recurrent
cancer-associated variants (1 to 3 per sample) in ﬁve genes
(KRAS, NRAS, TP53, EGFR, and BRAF) were detected by at
least one of the four programs. Most of the variants, 11 of 15
(73%), had VAFs ranging between 24.6% and 86.7% and
were detected by all four programs (Table 2). However, four
variants (two KRAS codon 12, one in TP53, and another in
BRAF) were present at lower frequencies (2.2% to 22.4%)
and were called by only a subset of the programs. The
detection of these mirrored the performance observed in the
HapMap samples, with SAMtools missing all four low-
frequency variants and only VarScan2 detecting a TP53
variant present at 2.2%, whereas GATK and SPLINTER
detected three of the four low-frequency variants.
To further assess the ability of these programs to detect
low-frequency variants in FFPE samples, we used DNA from
two clinical specimens to generate samples with 50% and
20% mix proportions (25% and 10% expected minor sample
VAF, respectively) and conducted an analysis similar to the
HapMap mixes using 45 SNPs identiﬁed in each pure sam-
ple. The observed VAFs in these mixed samples were 16%
and 7% for the 50% and 20% mixes, respectively, likely due
to different DNA qualities and somatic copy number changes84in the tumors. Variant detection performance using these
samples was largely consistent with that observed in the
HapMap mixes. SAMtools detected <15% of the variants in
both mixes, and GATK detected 93% (42 of 45) of the var-
iants in the 50% mix and 7% (3 of 45) in the 20% mix.
VarScan2 detected 100% of the variants in the 50% mix and
93% (42 of 45) in the 20%mix; SPLINTER detected 80% (36
of 45) in both samples, with most missed sites due to low
coverage. Overall, the results from both of these mixed
samples and the pure clinical specimens supported those
from the HapMap samples and showed that performance was
similar using data from FFPE specimens. Detection perfor-
mance in the pure clinical samples demonstrated that using
SAMtools for somatic mutation detection may miss poten-
tially relevant mutations because of low variant frequency.Discussion
Next-generation sequencing in the clinical laboratory has
become a practical alternative to conventional molecular
techniques for detecting mutations. Testing for somatic
mutations in cancer is a natural application for NGS because
it enables multiplex testing of numerous cancer genes sim-
ultaneously, and deep sequencing can potentially detect
low-frequency somatic mutations inherent in cancer speci-
mens because of contamination with nontumor cells andjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 5 Sensitivity and false positive calls
made using only ﬁltered reads compared with using
all reads. Filtered reads included only those with a
mapping quality >20, a minimum base quality of
20 for all bases, and no more than four discrep-
ancies. A: Sensitivity for minor gold standard SNVs
across all four programs after ﬁltering of low-
quality and multiple-discrepancy reads. Error bars
show the 95% binomial CI for each point estimate.
B: False positive SNV calls (mean per sample) using
high-quality reads compared with all reads. Error
bars show the SD across all samples at each mix
proportion (nZ 4).
Low-Frequency NGS Variant Detectiontumor heterogeneity. Although the high throughput of NGS
platforms and the digital nature of the resulting data make
detection of low-frequency variants technically possible, the
relatively high error rate of NGS platforms necessitates
methods that are able to differentiate true variants from
background noise.
In the present study, we assessed the ability of commonly
used NGS analysis programs to detect low-frequency vari-
ants in high-coverage (>1000) targeted NGS data using
synthetic laboratory-derived mixtures of HapMap samples.
Sequencing of these mixed samples showed no evidence for
bias against non-reference alleles in targeted hybridization
capture NGS data, and analysis of variant calls at known
gold standard variant positions obtained by independent
sequencing of the pure HapMap samples revealed substantial
variability in sensitivity for low-frequency variants across the
programs evaluated. We found that the variant identiﬁcation
function of the popular and widely used SAMtools program
is particularly insensitive to low-frequency variants and
would be poorly suited for a bioinformatics pipeline for deTable 2 Detection of Recurrent Somatic Mutations in 15 FFPE Lung A
Case Gene Variant Amino acid change Coverage
1 KRAS c.G35T p.G12V 3610
2 No recurrent SNVs detected
3 EGFR c.T2573G p.L858R 3055
4 NRAS c.A182T p.Q61L 1875
5 No recurrent SNVs detected
6 KRAS c.G35C p.G12A 2128
TP53 c.A840T p.R280S 730
TP53 c.G734A p.G245D 407
7 No recurrent SNVs detected
8 KRAS c.G35T p.G12V 1505
9 TP53 c.C380T p.S127F 985
10 TP53 c.G517A p.V173 mol/L 791
11 KRAS c.G35T p.G12V 3430
12 TP53 c.C331A p.L111 mol/L 906
BRAF c.C897A p.I300V 1238
13 KRAS c.G35T p.G12V 1098
14 TP53 c.G733T p.G245C 548
15 TP53 c.G818T p.R273L 1389
ND, not detected; SNVs, single nucleotide variants; VAF, variant allele fraction
The Journal of Molecular Diagnostics - jmd.amjpathol.orgnovo detection of somatic mutations in cancer specimens.
The GATK variant caller demonstrated good sensitivity
(97%) for variants with VAFs of approximately 10% but was
unable to detect variants present at lower frequencies. Var-
Scan2 and SPLINTER demonstrated the best performance
and detected>89% of variant VAFs as low as approximately
4% on the basis of observed VAFs in our mixed samples,
with even higher sensitivity in coding regions. We also
conducted a limited analysis of indel detection performance
using a small number of Sanger-validated indel variants and
found that only VarScan2 and SPLINTERwere able to detect
any indels below 25%. However, our set of validated indels
included only ﬁve distinct variants, all of which were non-
coding, and thus these results may not be generalizable. As
expected, detection of SNVs depended on coverage, with
most missed calls occurring at positions with relatively low
coverage (<200) and the most robust detection occurring at
a minimum coverage of approximately 400. Because
coverage in targeted NGS data can be quite variable, even
higher mean target coverage would be required to ensure thatdenocarcinoma Samples
VAF, % SAMtools GATK VarScan2 SPLINTER
53.8 þ þ þ þ
e e e e
25.7 þ þ þ þ
67.8 þ þ þ þ
e e e e
60.9 þ þ þ þ
42.5 þ þ þ þ
2.2 ND ND þ ND
e e e e
20.7 ND þ þ þ
54.6 þ þ þ þ
38.7 þ þ þ þ
54.8 þ þ þ þ
24.6 þ þ þ þ
14 ND þ þ þ
22.4 ND þ þ þ
27 þ þ þ þ
86.7 þ þ þ þ
; þ, positive; e, negative.
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Spencer et althis coverage level is achieved at all critical positions in an
NGS assay. Although higher coverage improved sensitivity,
it was associated with more false positive variant calls, in
particular with VarScan2, although speciﬁcity could be
improved by ﬁltering sequencing reads to eliminate those
with low quality and questionable alignments. SPLINTER
exhibited the opposite trend, with a large number of false
positive calls in the low-coverage data (<200) and few at
higher coverage levels. It is important to note, however, that
the PPV of all callers for coding region variants was high. In
these data, we observed only one coding region false positive
call, a variant with a VAF of 1% made by VarScan2, which
suggests that clinically relevant false positives are infrequent
in high-coverage targeted NGS data. Finally, we used these
programs to detect variants in a set of targeted sequence data
from lung adenocarcinoma samples and found similar per-
formance and results. Several variants were identiﬁed at ca-
nonical loci (eg, KRAS codon 12) that were at low frequency
and thus were detected by only the best-performing software
evaluated in the present study.
These results provide some guidance to molecular diag-
nostic laboratories as they design and implement NGS-based
assays for somatic mutations in samples for either clinical
testing or research studies. We tested two of the most
commonly used open source NGS analysis tools, SAMtools
and GATK, which were not designed for somatic mutation
detection in NGS data but nonetheless might be the initial
choice for laboratories implementing a test for cancer-
associated somatic mutations because of their availability
and widespread use as reported in the literature. The general
conclusions of the present study with respect to these
particular programs would likely be discovered early in the
validation process of a clinical test; however, the range of mix
proportions and the coverage analysis we performed should
provide laboratories with more detailed performance char-
acteristics for the common analysis tools we evaluated when
applied to deep coverage capture enrichment NGS data tar-
geted to any locus. Because our study also included DNA
from FFPE samples, we believe our observations can be
generalized to routine clinical testing that typically involves
this specimen type. In addition, we believe our mixing study
design, using well-characterized HapMap samples, is an
example of the type of experiment that could be implemented
for initial test validation and for routine quality assurance/
quality control in the clinical laboratory.
In the present study we also compared the performance of
the common general purpose NGS software tools SAMtools
and GATK with that of VarScan2 and SPLINTER, the latter
of which is a specialized program that requires spiked-in
control sequences to establish run-dependent error models.
The sensitivity of this program at low VAFs (approximately
4%) was higher than that of GATK and SAMtools and
was similar to that of VarScan2, while maintaining higher
speciﬁcity. However, the algorithm used by SPLINTER
requires high coverage depth for acceptable performance,
which was demonstrated in our study by the lower86sensitivity and greater number of false positive calls at lower
coverage (eg, <200). Because SPLINTER relies on spike-
in control samples to calibrate internal error models, control
reagents must also be included in the assay design. Control
sequences are already part of the standard NGS workﬂow
(eg, the phiX sequencing control), and these can double as
controls for SPLINTER without additional cost or inputs.
Our data suggest substantial beneﬁt of using SPLINTER
rather than SAMtools or GATK; however, its performance
is similar to that of VarScan2; eg, the sensitivity of
VarScan2 seems to be at least as good as, if not better than,
SPLINTER, and VarScan2 made only one false positive call
in a coding region across all cases in our dataset, which
occurred at a VAF of 1%, the practical lower limit of the
sequencing platform. Although we found that VarScan2
produces a relatively large number of likely false positive
calls in noncoding regions, this can be reduced substantially
by using a preﬁltering step to remove reads with a high
number of discrepancies. In our experiments, removing
reads with more than four discrepancies reduced the mean
number of likely false positive SNVs from approximately
20 in our target region to less than one. This approach has
been used by other groups and thus may be a general
method for increasing the speciﬁcity of NGS platforms.34
Although the present study explored some variables that
affect low-frequency variant sensitivity such as coverage
depth, other important variables were not examined. For
example, we used 1 mg of input DNA for library preparation,
which is equivalent to approximately 300,000 genome
copies; thus detection of low-frequency variants was not
limited because of low library complexity. Low input DNA
amounts could result in diminished sensitivity because of
sampling statistics, even at deep coverage levels. In addition,
we tested a single version of four variant identiﬁcation pro-
grams, although others have been developed. These may
perform differently, and future versions of the programs we
tested that incorporate improvements to the calling algo-
rithms or additional parameters could also change the per-
formance. However, any software that uses a bayesian
algorithm designed for constitutional variants, and there are
many in this category, would be expected to have limited
sensitivity because such methods anticipate only homozy-
gous and heterozygous variants.35e37 Another limitation of
the present study is that there were few gold standard insertion
or deletion variants. The few Sanger-validated indels that
were available for analysis offer some information about the
detection performance of the programs we tested, which was
largely similar to the performance for SNVs. Further, we have
previously found that other programs have good sensitivity
for larger indel events such asFLT3 insertions, which suggests
that NGS approaches can be used to identify low-frequency
indel variants in some cases.38 Inasmuch as the present study
was not designed to fully assess indel detection performance,
this will need to be addressed in future studies and/or valida-
tion experiments performed by individual laboratories using
gold standard indel variants obtained using other methods.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Low-Frequency NGS Variant DetectionThe lowest VAFs explored using the mixed samples in
the present study ranged between 2% and 4%, which we
believe is a reasonable lower limit of detection for tumor
sequencing from diagnostic tissue samples. Although the
clinical importance of detecting such low-frequency variants
is unclear, we note that conventional targeted methods for
detecting canonical mutations at a single position, such as
FLT3 D835 and KRAS codon 12 mutations, are often fairly
sensitive and can detect variants down to allele burdens of 3%
to 5%.39,40 These tests have been the basis for clinical assays
and numerous clinical studies and are routinely used to guide
clinicalmanagement of patients with cancer.41e44 The present
study demonstrates that standard NGS-based tests are at least
capable of achieving similar sensitivity. Somatic mutations
certainly exist at frequencies lower than those we explored, in
particular in the setting of minimal residual disease testing,
which often requires accurate detection of variants at fre-
quencies substantially <1%. Although it is possible that the
best-performing variant identiﬁcation tools may have reason-
able sensitivity below the lowest VAF examined in this study,
it is likely that current error rates of standard targeted NGS
make such platforms poorly suited for reliable discovery of
variants much below approximately 2% without compro-
mising speciﬁcity. In practice, we believe a low-tech approach
involvingmanual review of base counts at speciﬁc hot spot loci
with high a priori likelihood of somatic mutation (eg, KRAS
codon 12, FLT3 codon 835, and BRAF codon 600) provides a
means for sensitive detection of critical variants without
resulting in a large number of false positive calls that could
occur if a high-sensitivity approach is broadly applied across
the targeted genomic regions. Ultimately, it is likely that recent
advances in NGS methods that use molecular tags to increase
sequencing accuracy will replace these ad hoc methods and
enable reliable detection of low-frequency variants for cancer
testing and minimal residual disease assays.20,21,45
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